abstract | The outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells by causing them to elicit an immune response or alternatively, by increasing their susceptibility to immune attack. In addition, chemotherapy can stimulate anticancer immune effectors either in a direct fashion or by subverting immunosuppressive mechanisms. Beyond cancer-cell-intrinsic factors that determine the cytotoxic or cytostatic response, as well as the potential immunogenicity of tumor cells, the functional state of the host immune system has a major prognostic and predictive impact on the fate of cancer patients treated with conventional or targeted chemotherapies. In this Review, we surmise that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses.
Introduction
Despite research efforts, anticancer immunotherapies have only earned respectful attention by clinical onco logists over the past decade. For a long time, the only widely used immunotherapies were systemic injection of interleukin2 or interferon (iFn)α for the treatment of renalcell carcinoma, topical application of the tolllike receptor7 (tlr7) agonist imiquimod for the treatment of cutaneous basal cell carcinomas, and intravesicular instil lation of Bacille Calmette-Guérin for the treatment of superficial bladder carcinoma.
1,2 therapeutic mono clonal antibodies have also been introduced into the clinics, although the essential contribution of immune effector cells to their efficacy was only acknowledged when poly morphisms in immunoglobulin G fragment C receptors (which are indispensable for immune effectors to inter act with antibodydecorated tumor cells) were shown to dictate outcome. in 2010, the first patient specific immunotherapy (sipuleucelt) for advanced cancer -a dendritic cellbased vaccine against prostatic acid phosphatase -was approved by the FDa for the treat ment of androgenindependent prostate cancer. 3 in 2009, a promising trial demonstrated the thera peutic efficacy of large peptide antigens to eradicate vulvar intra epithelial neoplasias that are positive for human papilloma virus. 4 moreover, a phase iii trial showed that antibody mediated blockade of the immuno suppressive cytotoxic t lymphocyte antigen 4 with ipilimumab improved the survival of patients with metastatic melanoma. 5 the proof of principle of the effectiveness of immunebased therapy has been demonstrated by the surgery branch of the niH. they used adoptive tcell transfer to treat advanced melanoma and tcell alloreactivities that mediated a protective graftversusleukemia effect in the course of an allogeneic hemato poietic stemcell transplantation for leukemias. 6, 7 the exploitation of tumor immunology is relatively new to clinical practice. However, there is growing sus picion that, unexpectedly, the efficacy of many of the currently used chemotherapeutic agents depends on the active contribution of immune effectors. that is, clini cians who applied successful chemotherapeutic regimens may have unintentionally been taking advantage of the immune system's capacity to recognize tumorspecific or tumorassociated antigens and to control cancer (stem) cell growth. in this review, we will discuss the impact of immune parameters on the efficacy of chemo therapeutic regimens with small molecules, such as conventional (mostly cytotoxic) chemotherapeutic or targeted agents.
Scenarios in host-cancer equilibrium
During multistep carcinogenesis tumor cells progres sively accumulate mutations, which can either be 'drivers' (when they activate oncogenes or inactivate tumor suppressor genes) or 'bystanders' (when they affect irrelevant genes). these mutations also affect the primary sequence-and hence the antigenic properties -of proteins. 8, 9 the average human cancer cell acquires some ten mutations that yield unique, tumorspecific antigenic peptides, which can be presented by class i major histocompatibility complex (mHC) molecules to CD8 + t cells. 10 During dedifferentiation, tumor cells also acquire tumorassociated antigens, which are nonmutated, yet usually are not expressed by their nontransformed counterparts. 11 Beyond these changes in the antigenic profile, the oncogenic stress linked to early carcinogenesis (which is shut off in later tumor competing interests The authors declare no competing interests. 12, 13 may lead to the exposure of stress signals (such as nKG2D ligands or CD95), which increase the susceptibility of tumor cells to lysis by immune effectors expressing nKG2D or CD95 ligand.
14 oncogenic stress can also activate an intrinsic program of tumor suppres sion, causing apoptotic cell death (which may elicit an immune response) or senescence-a neartopermanent arrest in the cell cycle (which is tightly linked to the pro duction of proinflammatory cytokines).
12,13 as a result [14] [15] [16] experiments performed in mice, 15, 16 as well as circum stantial evidence obtained in humans, 17 suggest that tumors develop through three successive steps: elimination -when immune effectors succeed in destroying nearly all malignant cells, equilibrium-when the tumor and the immune system engage in a balanced struggle, and escape-when the tumor has succeeded in avoiding immune recognition and hence proliferates in an uncon trolled fashion. 15, 16 escape can result from active suppres sion of immune effectors, (immunosubversion), or from the loss of antigenic properties (immunoevasion). 18 what is the impact of chemotherapy on the relation ship between the tumor and the host immune system? the null hypothesis predicts that the chemo therapeutic agent only targets cancer cells (Figure 1 ). this hypo thesis, which excludes any impact of the immune system on the therapeutic response, is in line with the standard methodology of cancer drug development. Cytotoxic agents are selected based on their capacity to kill human cancers cells in vitro and then in vivo after their trans plantation into severely immunodeficient mice (in which the immune system obviously has no impact on the therapeutic response). 19 the negative hypothesis pre dicts that chemotherapy has major immuno suppressive adverse effects, thus preventing the immune system from contributing to its anticancer effects. indeed, one adverse effect of many genotoxic agents is a transient lympho penia, suggesting that quiescent memory cells (which can survive chemotherapy) or de novo generated immune repertoires would have to participate in the anticancer immune response, if such a response existed. moreover, it is assumed chemotherapy would select for stress resistant cancer cell variants that would also acquire resistance to an immune attack. the null and the negative hypotheses both exclude any active contribution of the immune system to the success of chemotherapy.
By contrast, the positive hypothesis, which we advo cate in this review, suggests that, at least in some cases, the immune system may contribute to make chemo therapy optimally efficient (Figure 1 ). there are several distinct, yet nonexclusive mechanisms through which genotoxic or targeted chemotherapeutics can change the relationship between the tumor and the immune system from escape to equilibrium or even elimination. through their action on cancer cells, chemotherapeutics can restore or enhance the expression of tumor antigens, making them more recognizable to the immune system. 20 Chemotherapy can also increase the susceptibility of tumor cells to lysis by immune effectors. thus, Dna damaging agents may activate p53independent and p53 dependent pathways that result in the upregulation of nKG2D ligands and CD95 (or other death receptors such as the tumor necrosis factorrelated apoptosis inducing ligand [trail] receptors Dr4 or Dr5), respectively. 14, 21 these pathways ultimately mimic those elicited by r e V i e W s oncogenic stress. additional mechanisms exist through which chemo therapeutics increase the susceptibility of tumor cells to lysis by cytotoxic t lymphocytes. For example, paclitaxel, cisplatin and doxorubicin cause the upregulation of mannose6phosphate receptors on the surface of murine tumor cells, which then become par ticularly sensitive to the cytotoxic effect of granzyme B, a protease contained in cytotoxic t lymphocyte gran ules. 22 moreover, a BraF inhibitor increases expression of melanocyte differentiation antigens on melanoma cells whose epitopes can be recognized by specific t cells. 23 it is tempting to speculate that these or similar mechanisms might contribute to synergy between chemotherapy and therapeutic vaccination that has been reported in mul tiple therapeutic trials. 19, 24 Beyond the broad impact of chemotherapeutics on the propensity of cancer cells to undergo lysis, some antitumor agents can also trigger immunogenic tumorcell death, 25, 26 causing the cancer cells to expose or secrete immunogenic signals that trigger an anticancer immune response.
some chemotherapeutics have direct effects on the immune system that may contribute to an improved anti cancer immunity (table 1) . For example, low metro nomic doses of cyclophosphamide (usually 50 mg/day for 3 weeks or a single 300 mg/m 2 dose) selectively deplete and/or inhibit regulatory t cells (t reg ), which have immuno suppressive properties.
27 taxanes can stimulate the pro liferation of t cells and the cytolytic activity of natural killer cells in patients with breast cancer (stage ii/iii), contravening traditional thinking that taxanes sup press immune cell functions.
28 moreover in mice, both gemcitabine and 5fluorouracil reduce the frequency of CD11b + Gr1 + myeloidderived suppressor cells in the tumor bed.
29,30 imatinib may inhibit the in vivo growth of murine tumor cells that do not respond in vitro, and this in vivo effect relies on the activation of natural killer cells. 31 indeed, in patients with gastrointestinal stromal tumors, imatinib can activate natural killer cells for iFnγ production, and this response predicts favorable clini cal outcome.
32 the immunerelated components of the abscopal effects of radiotherapy are being investigated. 33 indeed, geneexpression profiling of breast, prostate, and glioma tumor cells exposed to singledose (10 Gy) versus fractionated (2 Gy × 5) radiation revealed that only the fractionated regimen induced an iFnrelated gene signa ture (including STAT1).
34 these examples illustrate that there are mechanisms through which chemotherapeutic agents may restore the immunological equilibrium (or ideally, even the elimination) phase of tumors that have escaped from immunosurveillance, not only due to the 'debulking' of the tumor mass but also due to direct or indirect effects on the immune system. (table 2) . although these reports collectively establish that the immune infiltrate has prognostic value for the fate of the tumors and the patients, they do not reveal the pre dictive value of immune effectors. only a few reports have addressed the question 'do immune infiltrates affect the chemotherapeutic response?' in advanced ovarian carci noma treaded with platinumbased chemo therapy, patients who carry CD3 + tumorinfiltrating lymphocytes (tils) exhibit an optimal tumor debulking more fre quently than do patients lacking such tils.
Value of immune infiltrates in cancer
45,50 similarly,
in breast cancer treated with neoadjuvant chemotherapy (usually based on taxanes and/or anthra cyclines), the pres ence of tils, in particular t cells as well as mature den dritic cells, in the primary biopsy indepen dently predicts complete pathological responses. 51, 52 altogether, these results strongly support the notion that tumorinfiltrating immune effectors dictate the chemotherapeutic response of cancers, suggesting that their detection may yield invaluable information on the utility of current therapeutic protocols. the choice of appropriate methods to accurately characterize immune effectors within tumors, as well as the standardization of such methods constitutes a challenge for further clini cal development. moreover, appropriate image analysis 
Chemotherapy-elicited immune responses
Clinical oncologists are well aware of the fact that a state of disease or therapyinduced immunodeficiency predicts a dismal prognosis with no chemo therapeutic response. thus, severe lymphopenia (<1,000 cells/μl) negatively affects the chemotherapeutic response of multiple dis tinct solid cancers, as revealed by a large metaanalysis. 53 However, in contrast to animal experiments, these clini cal observations cannot measure the relative contribu tion of the expanding tumor mass and the deterior ating immune system to therapeutic failure. a collection of mouse cancers (including Ct26 colon cancer, mCa205 fibrosarcomas, tsa cellline breast cancers, Gos cell line osteosarcomas and el4 thymomas) respond to chemotherapy with anthra cyclines or oxaliplatin much more efficiently when they are implanted in syngenic immunocompetent mice than in immunodeficient hosts. 25,54 thus, the depletion of CD8 + t cells as well as the knockout of either iFnγ or the iFnγ receptor reduced the efficacy of chemotherapy to the same extent as the knockout of the rag2 recombinase (which have no B lymphocytes and t lymphocytes and hence manifest a complete immunodeficiency of the adaptive immu nity).
25,54 this observation is in line with the other clini cal studies revealing that iFnγproducing CD8 + t cells are potent anticancer immune effectors. 1, 37 these results raise the question whether and how cancer cells responding to chemotherapy can prime CD8 + t cells for iFnγ production. surprisingly, different types of chemotherapy are not equivalent in their capacity to induce immunogenic cancercell death. 55 in an assay monitoring the capacity of dying or dead cancer cells to elicit a protective immune response against rechallenge with live tumor cells, only four 
(oxaliplatin and three distinct anthracyclines) among 25 tested chemotherapeutics elicited immunogenic cell death. 26, 56 However, all the agents were highly cytotoxic and equivalent in their capacity to induce apoptosis. 26, 56 extensive biochemical analyses revealed the distinctive properties of immunogenic (but not nonimmunogenic) cell death. endoplasmic reticulum stress causes sublethal activation of caspase8 and exocytosis of endoplasmic reticulumderived vesicles, calreticulin, which is usually secluded in the lumen of the endoplasmic reticulum and relocates to the outer surface of the plasma membrane before cells become apoptotic. 57 this preapoptotic cal reticulin exposure is likewise an engulfment signal that allows dendritic cells, the essential antigenpresenting cells of the innate immune system, to take up portions of the stressed and dying tumor cell. suppression of the calreticulin exposure pathway 57 or depletion of cal reticulin 26,58 abolishes the immuno genicity of cell death induced by anthracyclines or oxaliplatin. Conversely, adsorbance of recombinant calreticulin protein to the surface of cells that undergo non immunogenic apop tosis (for example, in response to cisplatin) restores the immunogenicity of cell death.
26, 58 Blockade of cal reticulin exposure in colo rectal tumors negatively affects their chemo therapeutic response in immunocompetent mice, 59 suggesting that this immunogenic signal is indeed indis pensable for eliciting a therapeutic anticancer immune reaction (Figure 2 ).
Clinical studies in the past 2 years have validated the concept that calreticulin may affect anticancer immune responses in humans (table 3) . in colorectal cancer, the level of calreticulin expression on carcinoma cells is positively correlated with the presence of tumor infiltrating CD45ro + t cells, as well as favorable prog nosis. 60 this observation provides an intriguing link between immuno genic cell death and the intratumoral accumulation of memory effector t cells. in patients with acute myeloid leukemia (aml), the exposure of cal reticulin was associated with the capacity of CD8 + t cells to produce iFnγ upon stimulation with auto logous malignant myeloblasts. 61 importantly, low cal reticulin expression on aml blasts 61 correlated with high expression of CD47, a 'don't eat me' self protec tion signal that negatively affects the prognosis of aml patients. 62 the mechanisms of this correlation are elusive, although endoplasmic reticulum stress leading to the hyper phosphorylation of eukaryotic translation initia tion factor 2α (eiF2α) correlated with calreticulin expo sure on aml blasts. 61 these results suggest that eiF2α phosphorylation may constitute a surrogate marker for calreticulin exposure on tumor cells.
Beyond calreticulin exposure, cancer cells emit addi tional signals as they succumb to immunogenic cell death (Figure 2 ). one such signal has been identified as extracellular atP, which is secreted during the blebbing phase of apoptosis. 63, 64 another obligatory immuno genic r e V i e W s signal is high mobility group box 1 (HmGB1), which is normally associated with chromatin, yet can be released from apoptotic cells as they undergo secondary necro sis and the plasma membrane disrupts. 65, 66 thus, dying tumor cells that have depleted atP or HmGB1 are unable to induce an anticancer immune response when they are injected into mice. HmGB1 and atP act on tlr4 and a puri nergic receptor (P2rX7), respectively, which both are present on the surface of dendritic cells. 63, 65 tlr4 signals through a specific adaptor (myD88) to facilitate the pre sentation of tumor antigens by dendritic cells to CD8 + t cells and the production of prointerleukin1β (pro il1β). P2rX7 elicits the assembly of the nlrP3 inflam masome, leading to the activation of caspase1, which catalyzes the proteolytic maturation and consequent secretion of il1β that in turn is required for polarizing CD8 + t cell towards iFnγ production. in accordance with this scenario, mice that lack tlr4, myD88, P2rX7, nlrP3, caspase1, il1β or the il1β receptor are unable to mount an immune response against dying tumor cells. moreover, tumors implanted in mice deficient for tlr4, myD88, P2rX7, nlrP3, caspase1, il1β or the il1β receptor grow normally, yet fail to respond to chemo therapy with anthracyclines. 63, 65 similarly, blocking the interaction between il1β and its receptor is sufficient to reduce the efficacy of chemotherapy in several trans plantable or carcinogeninduced tumors. 63 together these results are compatible with a scenario in which anthra cyclines must trigger cancer cells to emit immuno genic signals that are sensed by dendritic cells, so that tumor cell death may elicit a productive anti cancer immune response (Figure 3) .
in Caucasians, the two receptors that capture signals from dying cells, tlr4 and P2rX7, are affected by single nucleotide polymorphisms that reduce their affinity for HmGB1 and atP, respectively. 67, 68 these lossof function alleles (TLR4 asp299Gly and P2RX7 Gly496ala) occurred at their expected allelic frequency in two cohorts of patients with breast cancer (stage t1n1m0) or colorectal cancer (m1). the TLR4 asp299Gly allele had a signifi cant negative impact on the progressionfree survival of patients with breast cancer (who received anthracycline based adjuvant chemotherapy) 65 and Dukes C colorectal cancers (who received oxaliplatinbased chemo therapy), 58 compared with patients bearing the normal TLR4 allele. By contrast, TLR4 asp299Gly had no effect on patients with colorectal cancer treated by surgery alone or those treated with 5fluorouracil (Dukes B), in line with the possibility that TLR4 asp299Gly is a predictive but not a prognostic factor. 58 among the patients with breast cancer that carried the normal TLR4 allele, the P2RX7 Gly496ala allele again reduced progressionfree sur vival. 63 these results (table 3) , which must be replicated in other cohorts, suggest that the deficient perception of immuno genic celldeath signals might reduce the efficacy of chemotherapy in human cancer. thus, they provide a tentative validation of the concept that anticancer immune responses contribute to the success of chemotherapy.
Conclusions
results from animal models and clinical studies can be con densed into a schematic (and highly speculative) pathway that links chemotherapy to an immune dependent thera peutic success (Figure 3) . as chemotherapeutic agents succeed in triggering immuno genic tumor celldeath the stressed and dying cancer cells release immuno genic signals. these signals are perceived by innate immune effectors (such as dendritic cells) to trigger a cognate immune response (that involves CD8 + t cells and iFnγ signaling), allowing the immune system to control resid ual tumor cells. if this speculation holds true, interrup tion of the pathway at any level would lead to therapeutic failure. thus, at a first level, a chemotherapeutic agent may be intrinsically unable to trigger immunogenic cell death. at a second level, tumor cells may be unable to emit the required set of immunogenic signals, such as when 
calreticulin exposure pathway is disabled. at a third level, the innate immune system may be unable to per ceive such immuno genic signals, due to defects in tlr4 or P2rX7 or their downstream signals and effectors, for example. Finally, local or systemic immuno suppression (for example, as a result of chemotherapy or radio therapy) or tumordependent immuno subversion and immuno evasion can prevent the formation, recruitment or action of cognate immune effectors, thus precipitating therapeutic failure and sealing the patient's inexorable fate (Figure 3) . largescale clinical studies are required to explore this scenario at all levels. at the level of pharmacology, pharmaco logical agents should be evaluated to identify those that induce immunogenic cell death and those that do not. at the level of cancer cellintrinsic charac teristics, the defects in immunogenic signaling should be investigated. regarding the properties of the innate immune system, the possible defects in the perception of immunogenic signals need to be identified. Finally, at the level of the interface between the immune system and the cognate immune effectors, the identification of mechanisms that can reduce the efficacy of the anti cancer immune response warrants further investigation. the formulation of appropriate questions, the use of systems biology methods, and largescale data integration of clini cal and biological information on the tumor and its host, should lead to the identification of novel prognostic and predictive biomarkers that account for immune para meters. we hope that these efforts will facilitate an ever more refined stratification of cancer patients and lead to an increasingly sophisticated or 'personalized' followup, treatment and cure.
Compensatory measures can be designed for each of the possible immunerelated defects causing therapeutic failure. in mice, individual cytotoxic chemo therapeutics that are unable to induce immunogenic cell death become more efficient when they are combined with agents that restore their immunogenicity. 69 the absent emission of immunogenic signals such as calreticulin exposure results in therapeutic failure, which can be overcome by restor ing the signal (for example, by injecting recombinant cal reticulin protein into the tumor). 59, 70 Genetic deficiencies in tlr4 blunt chemotherapeutic responses, which can be restored by stimulating different tlrs 54 or by sys temic treatment with chloroquine to improve dendritic cellmediated tumor antigen presentation. 65 similarly, recombinant il1β can overcome the defect in the immune response against dying tumor cells, character ized in P2rX7deficient mice. 63 Finally, each of the mul tiple immunosuppressive mechanisms that can explain the incapacity of immune effectors to attack tumor cells can be counteracted by therapeutic measures, as illus trated by clinical trials including those targeting cytotoxic t lymphocyte antigen 4, 3 PD1, 71 iDo, oX40, tGFβ, or il10. in this sense, the precise diagnosis of the immune defects that endanger the efficacy of anti cancer thera pies will allow the clinician to take individually adapted compensatory measures. 
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